|Bid||20.15 x 800|
|Ask||20.16 x 1200|
|Day's Range||20.06 - 20.31|
|52 Week Range||11.05 - 26.89|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||962.14|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
FT. MYERS, FL / ACCESSWIRE / October 1, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its Third quarter ...
FT. MYERS, FL / ACCESSWIRE / September 25, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Bill Bonello, Chief Strategy and Corporate ...
NeoGenomics, Inc. (NASDAQ:NEO) shareholders have seen the share price descend 14% over the month. But in stark...
During Friday's Lightning Round of Mad Money one caller asked about the Fort Meyers, FL headquartered NeoGenomics : "I won't say no to anyone working to cure cancer," replied Jim Cramer. NeoGenomics is a clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. In this daily bar chart of NEO, below, we can see that prices more than doubled this calendar year.
The Morgan Stanley conference presentation will be webcast live and accessible online via the investors section of the Company’s website, www.neogenomics.com. NeoGenomics, Inc. specializes in cancer genetic testing and information services.
NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Neo Performance Materials, Inc. (NASDAQ: NEO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 ...
FT. MYERS, FL / ACCESSWIRE / August 8, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, this morning filed an 8-K with the Securities and Exchange Commission ...
NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line. Earlier this week, NeoGenomics posted a quarterly beat.
FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetics testing services, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD® Laboratories central lab in Singapore. NeoGenomics’ Pharmaceutical Services Division has established a track record of rapid growth and is building a global network for clinical trials.
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Second-Quarter Highlights: Consolidated revenue increased 50% to $101.7 million Clinical Services revenue increased 49% to $89.0 million Pharma Services revenue increased 55% to $12.7 million Pharma Services ...
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MYERS, FL / ACCESSWIRE / July 9, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced that it intends to build a leading-edge cancer diagnostics testing facility and new global business headquarters in Fort Myers, Florida. Importantly, the site is a short drive from the existing NeoGenomics footprint in Fort Myers and remains in the vicinity of the Southwest Florida International Airport. The Florida Department of Economic Opportunity (“DEO”) and Lee County have agreed to support NeoGenomics’ expansion to encourage the company’s growth of high-paying jobs in a “high-impact sector” of the local economy.
FT MYERS, FL / ACCESSWIRE / July 1, 2019 / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2019 ...
FORT MYERS, FL / ACCESSWIRE / June 27, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that the company has entered into a new $250 ...
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Neogenomics Inc NASDAQ:NEOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for NEO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NEO are favorable, with net inflows of $1.27 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Cancer testing firm NeoGenomics broke out Thursday from a flat base, a couple of days after reporting strong earnings. NEO is stock of the day. Many cancer-testing firms are doing well.STOCK MARKET TODAY is sponsored by Interactive Brokers. To open an account, go to ibkr.com/whyib